Vav-iCre transgenic mice have the mouse HS21/45 control regions directing expression of an optimized variant of Cre recombinase (iCre) to hematopoietic cells (and their progenitors), and may be useful for generating conditional mutations in hematopoietic cells.
In Goodwin et al. 2019 Genome Res. 29:494, it was discovered that the transgene integrated into an intron of Commd10 (COMM domain containing 10) on chromosome 18 - creating a Commd10 null allele.
Genetic Background | Generation |
---|---|
|
Allele Type |
---|
Transgenic (Recombinase-expressing, Null/Knockout) |
It should be noted that the phenotype of these C57BL/6NJ-congenic Vav-iCre transgenic mice (Stock No. 018968) could vary from that of the parental line originally described on a different genetic background (Stock No. 008610). We may modify the C57BL/6NJ-congenic strain description if necessary as published results become available.
Vav-iCre transgenic mice express an improved Cre recombinase (iCre) under the control of the mouse vav 1 oncogene (Vav1) promoter. The transgene integrated into an intron of Commd10 (COMM domain containing 10) on chromosome 18. The insertion results in a functional knock-out of Commd10 in homozygous mice.
Mice hemizygous for this Vav-iCre transgene are viable and fertile, with the mouse HS21/45-vav control regions directing expression of an optimized variant of Cre recombinase (iCre) to hematopoietic cells (and their progenitors). Using crosses to a reporter strain, variegated germ line (testis and ovaries), and heart and gut expression is also reported. When bred with mice containing a loxP-flanked sequence of interest, Cre-mediated recombination will result in deletion of the floxed sequence(s) in the offspring. These Vav-iCre transgenic mice may be useful for generating conditional mutations in hematopoietic cells.
Joseph et al. 2013 Cell Stem Cell 13:520 reports that Vav-iCre mice express iCre in hematopoietic cells and endothelial cells, as well as in the testes. For Cre-lox experiments and to avoid/minimize germline deletion of the floxed allele, researchers may consider breeding Vav-iCre females with floxed males. However, female germline expression may also be observed (see below).
If the recombinase activity pattern of this allele is further characterized by the Genetic Resource Science group at The Jackson Laboratory, such findings will be reported on the Mouse Genome Informatics (MGI) Allele Detail entry (Commd10Tg(Vav1-icre)A2Kio). This same information would also be found searching the MGI Recombinase Activity database.
The Vav-iCre strain allows reliable deletion of specific genes throughout the entire hematopoietic compartment, whereas the hCD2-iCre strain (Stock No. 008520) allows targeting to be focused to T cells and B cells.
To be more suitable for use with C57BL/6N-congenic Knockout Mouse Project (KOMP) strains with floxed alleles, The Jackson Laboratory Repository chose several Cre recombinase-expressing strains and backcrossed them onto the C57BL/6N genetic background using a marker-assisted, speed-congenic approach. This approach employed 148 single nucleotide polymorphism (SNP) markers that differ between the C57BL/6N and C57BL/6J substrains, covering all 19 chromosomes and the X chromosome. For Stock No. 018968, this analysis determined that the colony has at least 143/148 markers (97%) as C57BL/6N allele-type. Because 3 of the 5 segregating markers are on chromosome 18 (~15.4-72.4 Mbp), this region may represent the transgene insertion site. In 2018, it was discovered that the transgene integrated into the Commd10 locus on chromosome 18.
The Vav-iCre transgene was generated in (CBA/Ca x C57BL/10)F1 fertilized oocytes and then backcrossed onto the C57BL/6J genetic background prior to arrival at The Jackson Laboratory Repository in 2009 as Stock No. 008610. In 2012, some Stock No. 008610 mice were bred to C57BL/6NJ inbred mice (Stock No. 005304) for many generations using a marker-assisted, speed congenic approach to generate this C57BL/6NJ-congenic strain as Stock No. 018968. This approach employed 148 single nucleotide polymorphism (SNP) markers that differ between the C57BL/6N and C57BL/6J substrains, covering all 19 chromosomes and the X chromosome. This analysis determined that the colony has at least 143/148 markers (97%) as C57BL/6N allele-type.
In 2018, it was discovered that the transgene integrated into an intron of Commd10 (COMM domain containing 10) on chromosome 18 - creating a Commd10 null allele.
Expressed Gene | cre, cre recombinase, bacteriophage P1 |
---|---|
Site of Expression | Cre recombinase is expressed in lymph nodes, thymus, spleen, Peyer's patches, intestinal cryptopatches, ovaries and testes. |
Allele Name | transgene insertion A2, Dimitris Kioussis |
---|---|
Allele Type | Transgenic (Recombinase-expressing, Null/Knockout) |
Allele Synonym(s) | Tg(Vav1-cre)1Kio; Tg(Vav1-cre)A2Kio; Tg(Vav1-icre)A2Kio; Vav1 (HS21/5)-iCre; Vav1-Cre; VavCre; Vav-cre; VavCredeBoer; Vav-iCre |
Gene Symbol and Name | Commd10, COMM domain containing 10 |
Gene Synonym(s) | |
Promoter | Vav1, vav 1 oncogene, mouse, laboratory |
Expressed Gene | cre, cre recombinase, bacteriophage P1 |
Site of Expression | Cre recombinase is expressed in lymph nodes, thymus, spleen, Peyer's patches, intestinal cryptopatches, ovaries and testes. |
Strain of Origin | (CBA/Ca x C57BL/10)F2 |
Chromosome | 18 |
Molecular Note | This transgene expresses Cre recombinase under the control of a vav promoter. This promoter was shown to be active in lymph nodes, thymus, spleen, Peyer's patches, intestinal cryptopatches, ovaries and testes. Line A2 inserted into the gene at 47022629-47022630 (Build GRCm38/mm10). The insetion results in a functional knock-out in homozygous mice. |
Mutations Made By | Dimitris Kioussis, MRC Natl Inst for Med Research |
Mice were bred to C57BL/6NJ inbred mice (Stock No. 005304) for many generations using a marker-assisted, speed congenic approach to generate this C57BL/6NJ-congenic strain. When maintaining the live congenic colony, hemizygous mice may be bred with wildtype (noncarrier) mice from the colony or with C57BL/6NJ inbred mice. Of note, the donating investigator of the parental line on a C57BL/6-congenic background (Stock No. 008610) reported that homozygous mice are not viable.
Joseph et al. 2013 Cell Stem Cell 13:520 reports that Vav-iCre mice express iCre in hematopoietic cells and endothelial cells, as well as in the testes. For Cre-lox experiments and to avoid/minimize germline deletion of the floxed allele, researchers may consider breeding Vav-iCre females with floxed males. However, female germline expression may also be observed (see the Mouse Genome Informatics (MGI) Allele Detail entry: Commd10Tg(Vav1-icre)A2Kio).
When using the Vav-iCre mouse strain in a publication, please cite the originating article(s) and include JAX stock #018968 in your Materials and Methods section.
Facility Barrier Level Descriptions
Service/Product | Description | Price |
---|---|---|
Hemizygous or Non Carrier for Tg(Vav1-cre)A2Kio |
Frozen Mouse Embryo | B6N.Cg-Commd10<Tg(Vav1-icre)A2Kio>/J Frozen Embryo | $2595.00 |
Frozen Mouse Embryo | B6N.Cg-Commd10<Tg(Vav1-icre)A2Kio>/J Frozen Embryo | $2595.00 |
Frozen Mouse Embryo | B6N.Cg-Commd10<Tg(Vav1-icre)A2Kio>/J Frozen Embryo | $3373.50 |
Frozen Mouse Embryo | B6N.Cg-Commd10<Tg(Vav1-icre)A2Kio>/J Frozen Embryo | $3373.50 |
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project. We do not guarantee breeding performance and therefore suggest that investigators order more than one breeding pair to avoid delays in their research.
What information were you hoping to find through your search?
How easy was it to find what you were looking for?
We may wish to follow up with you. Enter your email if you are happy for us to connect and reachout to you with more questions.
Please Enter a Valid Email Address
Thank you for sharing your feedback! We are working on improving the JAX Mice search. Come back soon for exciting changes.